Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Astellas Pharma Global Development Inc.
Sponsor

Astellas Pharma Global Development Inc.

United States 2375 Waterview Drive, 60062-6145, United States

About the sponsor

Research activity centers on gastric cancer, gastroesophageal junction adenocarcinoma, metastatic pancreatic adenocarcinoma, and related advanced solid tumors, with emphasis on tumors defined by CLDN18.2 expression and HER2-negative disease.

  • Gastric adenocarcinoma
  • Gastroesophageal junction adenocarcinoma
  • CLDN18.2-positive tumors
  • Metastatic pancreatic adenocarcinoma

The portfolio also includes studies in locally advanced unresectable and metastatic upper gastrointestinal disease.

About Specializations

Astellas Pharma Global Development Inc. runs clinical trials in conditions such as Adenocarcinoma gastric, Oesophageal adenocarcinoma, Acute myeloid leukaemia, Bladder cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

16 clinical trials

Bladder cancer

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Astellas Pharma Global Development Inc.

Prostate cancer

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astellas Pharma Global Development Inc.

Prostate cancer metastatic

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Nephrogenic anaemia

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Epoetin Alfa
  • Sponsor:Astellas Pharma Global Development Inc.

Hot flush

Not recruiting
Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fezolinetant
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma gastric+3

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma gastric

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma gastric

Not recruiting
Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma gastric+1

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Astellas Pharma Global Development Inc.

Acute myeloid leukaemia

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Astellas Pharma Global Development Inc.

Acute myeloid leukaemia

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Astellas Pharma Global Development Inc.

Pancreatic carcinoma metastatic

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.